This page shows the latest multiple sclerosis drug news and features for those working in and with pharma, biotech and healthcare.
Swiss pharma company also provided key updates on a number of drug candidates in its pipeline. ... growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene
Johnson &Johnson’s (J&J) pharma division Janssen has announced that the US Food and Drug Administration (FDA) has approved its multiple sclerosis (MS) treatment ponesimod, under the brand name Ponvory. ... Every person with multiple sclerosis is
Path to approval looks increasingly difficult for potential Alzheimer’s treatment. A panel of outside experts met on Friday to examine data supporting Biogen’s new drug application for its potential ... spinal muscular atrophy drug Spinraza
Shares in Biogen skyrocketed by 32% following ruling. Biogen has scored its first major success of the year, winning a patent challenge from Mylan over its multiple sclerosis drug Tecfidera. ... The dispute was a significant one for Biogen – Tecfidera
BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to ... $94m. Meanwhile, Caforio is confident that
Following Cosentyx was Entresto, which grew by 71% in Q4 to $1.7bn, an impressive increase from the $430m Novartis posted for the drug in Q3. ... Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer
More from news
Approximately 0 fully matching, plus 145 partially matching documents found.
Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The key difference between DS-8201
Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee. ... The company has just secured 'Rapid Uptake' status for its multiple sclerosis drug Mavenclad via the new Accelerated Access Collaborative process
Not so. Take the example of this campaign for Sativex, a drug used in the treatment of Multiple Sclerosis.
Novartis faced similar difficulties in the UK when its multiple sclerosis drug Gilenya was declined by the National Institute for Health and Clinical Excellence (NICE) due to its comparator, Avonex, not ... High-end scenario planning capabilities will
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis
of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept). ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
In this article, we will examine three key disease areas: COPD, rheumatoid arthritis and multiple sclerosis to determine which drug types have been the winners and losers in terms of usage ... Multiple sclerosis. Multiple sclerosis presents a more
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.